have fostered a fighting spirit. Given this orientation, turning to hospice can seem like admitting failure, although hospice providers respond that patients are not asked to give up hope, but to change the idea of what is hoped for. The new generation of AIDS victims contains many more poor people, women, Africans, and African Americans, and many of these people may find hospice more acceptable. At the very least, new approaches to these new cohorts will be called for. Another obstacle to accepting AIDS patients has been a general fear of the disease and of contact with its victims. This is analogous to the fear of the use of morphine that early hospices have had to contend with and should respond to similar rational educational programs.
The Saunders and Kastenbaum book documents a few programs scattered about the world that already include AIDS patients, but so far experience is too limited to permit analysis of the problems and possibilities. AIDS may well be the next and perhaps the greatest challenge to the hospice movement, which has never shirked from difficulties. In one of the most severely afflicted countries, The Union of South Africa, hospice leaders, confronting the AIDS pandemic, have recognized that they cannot possibly cope with the numbers of projected terminal patients. Therefore, they are planning to increase training and education programs to mobilize more people in the community to provide care on their own. Can we in the more fortunate United States do moreaccept these sufferers as just as worthy of a humane deatn under the care of capable ana caring attendants as any victim of cancer or dementia?
The overall thrust of the books reviewed here makes it clear that hospice is universally practical and desirable, given the will and the effort. In fact, we can say that it has been tested, shown to be effective in providing care, economically efficient in doing so, and is now ready to be firmly incorporated into developing health care systems, including our own. That it is still not universally recommended may result from lack of experience with the good it can do. In many places, and particularly in this country, some of the strongest advocates for this service have been nonprofessionals. Families and friends who have experienced its benefits continue to be the most vocal proponents. Its full potential for humanizing the experience of dying, however, will not be realized until we have undertaken more extensive educational programs directed at health care professionals and the public. Strong advocacy for hospice has brought about the present Medicare financing for it, which, although it has made possible the development of the service in the United States, is complicated and sometimes seems to be more of a barrier than a help. Additional efforts will still be needed to make hospice care a fully reimbursable part of overall health care, available to all. To provide hospice care to everyone who is afflicted witn any kind of progressive terminal illness and who chooses to accept it, personally or by proxy, is a task we can and must undertake now.
Reading the three books that provide the background for this essay, one quickly realizes the difficulty in assimilating the breadth of information on the aging human nervous system into a compendium. The overwhelming theme common to these volumes is the underlying dynamic complexity of the human brain, exhibited as a continuum from the earliest stages of development onto and throughout old age. This complexity is highlighted through an examination of the brain as an organ subject to ever-changing internal and external environments that constantly threaten the homeostatic balance in maintaining normal functioning. The potential abilities and capabilities of an adaptive nervous system are brought into clear focus as the information pertaining to the developing and aging brain unfolds in Brain Plasticity: Development and Aging, edited by Guido Filogamo, Antonia Vernadakis, Fulvia Gremo, Alain M. Privat, and Paola S. Timiras. In Free Radicals in Brain Physiology and Disorders, edited by Lester Packer, Midori Hiramastsu, and Toshikazu Yoshikawa, the reader is quickly confronted with the nature and characteristics of free radicals, how they pertain to generalized cell damage, and their roles in the brain as mediators of neuronal damage and toxicity. Similarly, the Handbook of the Aging Brain, edited by Eugenia Wang and D. Stephen Snyder, demonstrates a dichotomy between normal and abnormal aging in the human brain with a focus on the pathological dispositions observed in a number of neurological disorders that appear as a function of age. Taken together, these three books therefore offer the reader a very good understanding of our fairly current knowledge of the spectrum of tne aging brain with insight into the important questions that researchers are and will be addressing in the next millennium.
There are numerous areas of neurobiology that pertain directly to the field of gerontology, but one stands out as encompassing the very essence of how aging has a dramatic effect on neurobiological systems, that being free radicals within the central nervous system. Aging, as it pertains to brain oxidative damage, demonstrates the vulnerability that the aging brain has to normal metabolic processes and to stressors encountered with age that can result in severely debilitated functionality. This topic is covered explicitly in Free Radicals in Brain Physiology and Disorders, a must read for students, researchers, and clinicians across disciplines. The importance of the role of free radicals in the aging brain is highlighted with chapters on Parkinson's disease, epilepsy and injury, ischemia, and Alzheimer's disease (AD).
As an AD researcher, free radical generation and subsequent effects are of great import for my investigations on stimuli and outcomes of inflammation important in our understanding of the neurodegenerative processes ongoing in the Alzheimer brain. In this regard, the relationship of free radicals to the damage in selectively vulnerable areas of the brain provides insight into the mechanism(s) that may directly affect the neurodegeneration characteristic of AD. The role of one free radical in particular, nitric oxide (NO), is well described in two different chapters of the aforementioned books, in "Features and Functions of Human Microglial Cells," by Gremo and colleagues in Brain Plasticity: Development and Aging, and in "Pathologic Roles of Nitric Oxide in the Central Nervous System," by Dawson and Dawson in Free Radicals in Brain Physiology and Disorders. In particular, the roles that microglia and astroglia play in the cascade of events leading to the expression of NO synthase, and subsequently NO production, highlights a potentially key feature of a pathway in which one could envisage the ultimate production of (3-amyloid and neurofibrillary tangles, both hallmarks of AD. The involvement of these glial cells as modulators of the pathogenetic process characteristic of AD is becoming more appreciated and accepted with our increasing knowledge of their functional capacities. The recognition of the multiple roles for which these glial cells are important can be viewed as a "double-edged sword." It is becoming increasingly clear that they have the capacity to be both antagonistic and protagonistic in their role to maintain the proper homeostatic environment in the aging brain. Likewise, on the molecular level, NO in the brain serves as an example of how both the necessary and detrimental effects of its production could influence the health of a neuron or result in neuronal cell death. This provides an excellent example of the homeostatic balance required for maintenance of normal function in the aging brain. Under normal conditions, NO has been postulated to be involved in the regulation of gene expression, neurotransmission, morphogenesis, and synaptic plasticity. However, under conditions of duress in the nervous system, overproduction of NO may result in damage to surrounding neuronal and glial cells, thereby stimulating dramatic neurodegenerative consequences. These consequences may arise from numerous insults to the brain, including ischemia, stroke, trauma, and infection, and at least at one level, consist of the formation of peroxynitrite following the interaction of NO with other generated free radicals such as the superoxide anion. Peroxynitrite may very well damage neuronal cell membranes, thereby stimulating a cascade of events resulting in neuronal degeneration and death. Interestingly, in AD the accumulation of (3-amyloid itself may provide the stimulus for the generation of peroxide and other free radicals, setting the stage for neurodegeneration.
In their chapter, Dawson and Dawson outline a mechanism of NO-mediated neurotoxicity which combines features of N-methyl-D-aspartate (NMDA) receptor-mediated excitotoxicity, Ca 2+ activation of NO synthase, DNA and mitochondrial damage, and eventual cell death. This mechanism of NMDA receptor activation by glutamate causes an increase in the influx of calcium that could subsequently activate the calcium-dependent enzyme-NO synthase-among other proteins, thereby generating NO and other free radicals. In addition, calcium release from intracellular stores may elicit the production of additional free radical molecules. NO alone, or in combination with superoxide radicals to form peroxynitrite, further damages DNA and mitochondria resulting in increased free radical production. Ultimately the cell is depleted of energy stores and undergoes degeneration and death. This scenario appears to be quite feasible and probable and, as Dawson and Dawson make clear, has been validated through numerous studies that prevent or inhibit the generation of free radicals with superoxide dismutase.
Given the existing state of knowledge on the potential for free radical generation and damage in the nervous system, how does this model fit with diseases containing both genetic and nongenetic features that result in similar outcomes such as in familial and sporadic AD? The complexities of AD and other neurodegenerative conditions are well-described in the Handbook of the Aging Brain, and the focus on the pathology is well-documented. What is absent, however, is a unifying approach in consideration of neurodegenerative diseases that display genetic familial -components, but in addition have no identified genetic etiology and fall within the realm of sporadic disease. In this regard, let us use AD as an example, albeit numerous neurodegenerative conditions could be exemplified here.
A most obvious impression is to assert that there is a unifying theory in both the familial forms of AD and late-onset sporadic AD, because of some of the pathological hallmarks that are characterized in each-(3-amyloid deposition in neuritic senile plaques, neurofibrillary tangles in neurons, and neuropil threads in neuronal processes. However, although there is very strong evidence that (3-amyloid accumulation and deposition is a most likely initiator and predecessor of the pathogenesis process in familial AD followed by other pathology, the same is not necessarily obvious in the more common sporadic form of AD. Because causative agent(s) for this latter form of AD have yet to be clearly defined and identified, we can only speculate as to the initiators of the pathological process. However, given the similarities in the deposits of P-amyloid in familial and sporadic AD, one is tempted to focus upon this entity as critical to the pathogenetic process.
How do we reconcile this issue in light of not fully knowing the stimuli for the deposition of (3-amyloid in sporadic AD? The easiest approach is to conclude that (3-amyloid is the cause of AD in general because of its deposition and resulting pathology observed in familial AD, so by default numerous investigations are or have been based upon this hypothesis. This conclusion, however, leads us to question just why and how (3-amyloid would be accumulating into similar deposits in the nongenetically based disease. This leads us to consider that sporadic AD does not start with the accumulation of |3-amyloid, although (3-amyloid would most obviously have a great effect on the neuronal and glial environment upon its ultimate deposition.
What then could truly unify these two forms of AD? To address this question, we have to digress and examine the status OT the protein deposits that accumulate not only in the brains of familial and sporadic AD individuals, but also in aged normal brains. What is important is to uncover the potential common pathways leading to the generation of the well-characterized protein deposits.
Protein depositions indicate that certain proteins are vulnerable to modifications during the aging process, both in normal and pathological conditions, that result in their accumulation in the human brain. These deposits provide us with clues into the pathologic processes that are occurring in neurodegenerative conditions. But, just what are those processes and how do they manifest themselves in the aging nervous system? This question is the essence and focus of the Handbook of the Aging Brain, in which the aging brain is described more frequently in terms of the pathology associated with the brain rather than in terms of normal processes of the aged nervous system manifested as a function of the aging process. It seems to be far easier to highlight pathology with the intent to decipher what is abnormal in the aged brain as compared to brains showing no or little recognizable pathology (and therefore considered to be normal), than to compare normal brains of differing ages and determine which functions or dysfunctions can now be attributed to the aging process.
Obviously, there are many differences in normal aging and abnormal aging in the nervous system. The Handbook of the Aging Brain does address this issue through chapters describing normal and abnormal memory, normal aging as compared to AD, and the genetic analysis of neural aging. However, what is clear From these chapters is that there is still ongoing debate as to how to truly differentiate normal aging from abnormal aging, and whether there is a continuum or dichotomy between these aging processes. This debate stems from observations indicating that within normal aged brains, protein accumulations are found that would be similar to those observed in abnormal or diseased brains, but to a far less extent. Upon analysis, one realizes that the accumulations are made of the same or similar protein components in both cases.
How does one resolve this issue and what really are the important aspects of these findings? There are several issues of import here. What can be deciphered from analyzing the quantity versus the quality of abnormal protein accumulation? Does the quality of the accumulated material have greater import for our understanding of where and in what cell types we observe deposits of modified proteins? What can be derived from knowing that the same material can accumulate in both normal conditions and abnormal disease states? In answering these questions, we must realize that they all are important in the scheme of differentiating normal aging from abnormal aging. For example, quantities of inclusions such as neurofibrillary tangles in neurons and of deposits such as neuritic senile amyloid plaques help in the histopathological diagnosis of AD. The specific areas of the brain affected and the neurons damaged provide a qualitative understanding and relationship of pathology to disease symptomatology. Likewise, evidence that the same proteins are involved in the accumulations observed in normal brains as compared to diseased brains suggest that at some level a similar pathway is invoked that results in an outcome in which the most obvious difference from diseased brains is the quantity of depositions. Explanations for this outcome may come from our limited understanding, to date, of how (3-amyloid deposits and neurofibrillary tangles are derived in the pathological state.
The tendencies in the research community have been to focus more on the phenomena of accumulation than on potential causations of the phenomena. Often it is stated that the deposit may be causative for the disease. Conversely, the deposits may only be symptoms or outcomes of the disease process. In numerous ways, both statements may very well be accurate. For example, in familial AD the deposition of (3-amyloid (AfM is facilitated as a consequence of mutations in the genes for the amyloid precursor protein and the presenilin proteins (PS-1, PS-2). The accumulation of A042 may very well activate microglia and astroglia resulting in an inflammatory response in the brain that is the true culprit in the generation of severe neuronal damage. This damage could result from numerous insults, including cytokine exposure, glutamate-mediated excitotoxicity, free radical generation and damage to DNA and proteins, and stimulation of systemic inflammatory modulators.
There appears to be a general acceptance for the role of inflammation in contributing to the extensive damage observed in the AD brain. How would this process in familial AD compare and contrast to the much more common form of late-onset sporadic AD? The commonality surfaces again with the accumulation of amyloid. What may be highly possible is a scenario that involves one or multiple triggering events that first stimulates an inflammatory process that results in initial cell damage in the brain. Subsequently, this damage may lead to the specific accumulation of abnormally processed amyloid into A042 and AfW forms that then proceed to stimulate a feedback mechanism, which now acts as a second trigger to exacerbate a microglial and astroglial response, thereby closing the circle of inflammatory mediation in the AD brain.
What kind of initial triggering event would be required? Evidence from numerous investigations supports hypotheses proposing that apolipoprotein-E allelic genotype, ischemia, stroke, trauma, and infection could be potential mediators or "hits" in the nervous system resulting in the predisposition of an individual for the development of sporadic AD. All of these insults could result in the generation of inflammatory modulators that may lead to profound changes in a local environment whereby the systemic immune system as well as the microglia and astroglia within trie brain are activated. The level of acute and chronic inflammatory responses and the extent of insult to the brain would, most likely, dictate an individual's capacity to undergo cellular and tissue repair or degeneration. The most apparent signs of repair or degeneration may be the deposition of proteins both extracellularly and intracellularly as an outcome of the combinations of insults such as excitotoxicity, Ca 2+ activation of NO synthase, DNA and mitochondrial damage, and kinase and phosphatase activities, just to name a few.
A chronic state of disrepair or degeneration may be indicated with the deposition of |3-amyloid, which, in a fibrillogenic state, could act to exacerbate the inflammatory response exhibited by the microglia and astroglia in the brain. In this manner, the cycle of inflammatory stimuli would reveal an insidious feedback mechanism that promotes an ever-increasing amount of damage to the aged brain. This feedback scenario would, in essence, provide a second "hit" to the brain, which if unblocked or unmodified by therapeutic means would catapult into chronic neurodegeneration and eventual cell death.
In numerous chapters in the books reviewed as background for this essay, the therapeutic interventions discussed are highlighted in terms of their effects on inflammatory molecules directly or on the ultimate substrates of those inflammatory mediators such as the P-amyloid and tau deposits accumulating in the damaged brain. The existing therapeutic strategies may be of little value in stopping the progressive course of most of the neurodegenerative conditions mentioned in these important texts. However, strategies aimed at blocking or neutralizing the effects of free radicals, blocking enzymes such as cyclooxygenase, and inhibiting fibrillogenesis of proteins are taking center stage as we uncover critical features of the manifestation of numerous age-related neurodegenerative diseases.
The issue of protein deposition and accumulation in the brain piques one's curiosity as to why and how particular proteins appear to be preferentially involved in the pathogenesis process. Is there, in addition to an apparent selective vulnerability of neurons and regions of the brain, a selective vulnerability of the proteins and peptides that happen to accumulate in normal aged brains and in those with well-defined neurodegenerative disease? Could the accumulations of the tau protein into neurofibrillary tangles and (3-amyloid into senile plaques indicate that they are the hardier species of proteins that are affected in the pathogenesis process of AD? This hardiness may be a reflection of their inherent stability and/or of their susceptibility to modification leading to their greater resiliency to degradation. Reasoning behind this speculation is that less hardy and/or modified species of proteins, most probably, would be destroyed through enzymatic proteolysis resulting in more complete solubilization and dissolution. So, what do these deposits indicate? They may indicate that an ongoing process is occurring in which they become the modified, nonfunctional, nonproteolyzable by-products resulting from mechanisms encountered in both the "normal" and "abnormal" aging brain. Clues to the cause of such malformations may lie more in the way in which the proteins have been modified than in their specific identities as part of the insoluble complexes. Research has uncovered numerous mechanisms by which the proteins are modified as a function of aging. These include, but are hardly limited to, conformational changes such as beta-pleated sheet formation of associated peptides, modifications through the action of transglutaminase, glycation, racemization, and phosphorylation.
In returning to the comparisons of "normal" brain aging and that associated with disease, the similarities with regard to protein depositions and cell injury are striking. The forces of aging may encompass the inability in aging systems to maintain the proper homeostatic balance and thereby lead to cellular degeneration and death by evoKing pathways utilized in true disease processes. For example, in aging systems, oxidative free radical generation, which is always occurring in aerobic systems, may outweigh the cells' ability to neutralize the free radicals entirely. This could lead to protein modifications resulting in their deposition and accumulation, but in a far more limited capacity than what is observed in true disease states. In this instance, age itself would become a trigger or "hit" for what we have observed occurring in neurodegenerative diseases. However, age in and of itself is not a disease entity; it probably should be thought of as a diminished capacity to maintain a homeostatic balance in a system of diminished plasticity, such as the aged brain. In this way, age may predispose to the development of disease which may or may not occur, and therefore, changes with age should be thought of as dichotomous entities, and not as part of a pathogenetic continuum.
In summary, this essay has attempted to highlight the essence of the three books which are the subject of this review. Unfortunately, this essay can not due total justice to all of the wide-ranging and overlapping topics presented in these three overall excellent bodies of work on the aging brain. For the topics on which the essay has been focused, however, I believe that I am not alone in suggesting that they are all critical to our present and future understanding of the dynamic aging human nervous system. Hopefully, the perspectives outlined herein will continue to stimulate and to provoke discussions on the role of age as a participant in both normal brain aging and in defined neurodegenerative conditions. As ongoing and future research uncovers more defined causative entities for the many diseases associated with aging and, in particular, the aged brain, we will no doubt develop a clearer picture of why and how age and disease contribute to the plasticity, susceptibility, and vulnerability of the human brain in these manifestations. The books reviewed in this essay can be read in two broadly different ways. Read in the conventional way, as reports on the state of the art in the scientific study of dementia, they are impressive documents indeed (though not equally so, as we will describe in our discussion of each book below). Progress in understanding the clinical and pathological features of dementia and their biological basis is occurring at a tremendous rate, making books such as these an essential tool even for specialists in the field. But one can also examine these volumes from another perspective-questioning the social, epistemological, and moral implications of the way they frame the problems of dementia. From this perspective these books reflect ways in which our response to dementia may not be adequate.
The dementias pose complex problems, not all of which can be resolved through the technical cures that medical science strives so mightily to attain. Ideally, we should deal with dementia through a wideranging series of public and professional discourses that bridge disciplinary boundaries. But at this point, the production of knowledge remains highly compartmentalized: scientific literature aimed at scientists, ethical literature aimed at ethicists, and social science and humanities literature aimed at scholars in those fields-little of which is accessible to a general audience. It is troubling to observe that these various discourses on different aspects of the problem of dementia are almost entirely disconnected from one another (Whitehouse, 1999) .
In this essay we will first evaluate these books on their own terms, as contributions to or representative summaries of the scientific understanding of the dementias. We will conclude by discussing the problem of the compartmentalization of knowledge and the need for science to embrace broader perspectives to address adequately the problems of dementia.
As contributions to scientific understanding, the two books by research groups in the United Kingdom are excellent summaries of state-of-the-art work in these two topic areas. Ironically, the book edited by Marshal F. Folstein, although the most recently published of the three, is the most out of date. Four years elapsed between the conference in which the chapters were first presented and the eventual publication of the book-an eternity in a field in which new discoveries are announced nearly every day. Moreover, the scope of the book is considerably broader than its title suggests, discussing conditions such as the dementias associated with head trauma and poststroke major depression that are well beyond the category of primary dementia. For these reasons, it cannot be recommended as an accurate representation of state-of-the-art knowledge about the neurobiology of
